"Novo Nordisk plans to deploy advanced artificial intelligence capabilities to analyze complex datasets, identify promising drug candidates, and reduce the time required to move from research to patient."
"The company has structured its use of AI with strict data protection, governance, and human oversight to ensure ethical and compliant use."
"NovoScribe, an AI-powered platform, automates and accelerates the creation of clinical study reports, significantly reducing the time to regulatory submissions."
"External partnerships and collaborations will continue to play an important role in reaching Novo Nordisk's AI ambitions, including joining the Ligand-AI project funded by the EU."
Novo Nordisk collaborates with OpenAI to leverage AI in drug research and development. The partnership aims to analyze complex datasets, identify drug candidates, and expedite the research-to-patient timeline. Strict data protection and governance measures are in place to ensure ethical AI use. The company established an AI center of excellence in 2021 and has invested in high-performance computing. NovoScribe, an AI platform, automates clinical study report creation, reducing regulatory submission times. External collaborations are crucial for achieving AI goals, including participation in the Ligand-AI project for protein-ligand interaction datasets.
Read at ComputerWeekly.com
Unable to calculate read time
Collection
[
|
...
]